Rulisa Stephen, Gatarayiha Jean Philip, Kabarisa Tharcisse, Ndayisaba Gill
Central University Hospital of Kigali, Kigali, Rwanda.
Am J Trop Med Hyg. 2007 Oct;77(4):612-6.
In view of the changing policy towards artemisinin-based combination therapies (ACTs), the efficacy, tolerance, and degree of re-infection of two ACTs were investigated: artesunate plus sulfadoxine/pyrimethamine (As + SP) and AS plus sulfamethoxypyrazine/pyrimethamine (As + SMP). One hundred three children were assigned to receive As + SP and 109 to receive As + SMP. In spite of the high incidence of resistance to SP, As + SP showed satisfactory results consistent with recent recommendations for ACTs (adequate clinical and parasitologic response on day 28 [ACPR] > or = 90%), but results with As + SMP fulfilled the most stringent criteria (ACPR > or = 95%). The absence of side effects and the low price of these drugs make them it worth to reconsider national therapies in favor of either of these two drug combinations.
鉴于基于青蒿素的联合疗法（ACTs）政策的变化，对两种ACTs的疗效、耐受性和再感染程度进行了研究：青蒿琥酯加磺胺多辛/乙胺嘧啶（As + SP）和青蒿琥酯加磺胺甲氧吡嗪/乙胺嘧啶（As + SMP）。103名儿童被分配接受As + SP，109名儿童接受As + SMP。尽管对SP的耐药率很高，但As + SP仍显示出令人满意的结果，符合近期对ACTs的推荐（第28天的充分临床和寄生虫学反应[ACPR]≥90%），而As + SMP的结果符合最严格的标准（ACPR≥95%）。这些药物没有副作用且价格低廉，这使得值得重新考虑国家治疗方案，转而采用这两种药物组合中的任何一种。
